randomized clinical trials: the holy...
TRANSCRIPT
![Page 1: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/1.jpg)
Randomized Clinical Trials: the Holy Grail
![Page 2: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/2.jpg)
PRIMARY EFFICACY SUBGROUP RESULTS (mITT)
ASA
ASA + thienopyridine 0.86 (0.75 -0.98) 0.34 0.69 (0.45 -1.05)
STEMI NSTEMI UA
0.85 (0.70 - 1.03)
0.85 (0.68 - 1.06)
0.82 (0.62 - 1.07)
0.96
<65 Years
65 Years
0.83 (0.70 - 0.99)
0.84 (0.70 - 1.01)
0.94
Male
Female
0.87 (0.75 - 1.01)
0.77 (0.60 - 0.99)
0.40
Weight <60 kg
Weight 60 to <90 kg
Weight 90 kg
0.83 (0.56 - 1.25)
0.85 (0.72 - 0.99)
0.83 (0.64 - 1.08)
0.98
Prior MI
No Prior MI
0.83 (0.68 - 1.01)
0.85 (0.72 - 1.01)
0.80
0.5 0.8 1.25 2.0 1.0
Diabetes Mellitus
No Diabetes Mellitus
0.96 (0.77 - 1.20)
0.78 (0.67 - 0.92)
0.14
Creatinine Cl <50 mL /min
Creatinine Cl > 50 mL /min
0.88 (0.62 - 1.26)
0.84 (0.73 - 0.96)
0.82
0.57 (0.33 - 0.97) North America
South America Western Europe Eastern Europe
Asia Other
0.89 (0.59 - 1.34)
0.90 (0.59 - 1.37)
0.83 (0.69 - 1.00)
0.86 (0.63 - 1.17)
0.92 (0.60 - 1.39)
0.80
Overall 0.84 (0.74 0.96)
HR (95% CI) P interaction
Rivaroxaban Better Placebo Better
![Page 3: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/3.jpg)
RCTs and subgroup analysis
Study CURE (3) CURRENT OASIS 7(1) TRITON TIMI (3)* PLATO (7) CAPRIE(3) CHARISMA(3) RE-LY (6) ROCKET AF(1) ARISTOTLE
![Page 4: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/4.jpg)
…What it has been said about subgroup analysis
The answer to a RCT that does not confirm one’s beliefs is not the conduct of several subanalyses until one can see what one believes. Rather the answer is to re-examine one’s beliefs carefully. Subgroup analyses are particularly prone to over interpretation, and one is tempted to suggest ”don’t do it (or at least don’t believe it) for many trials, but this suggestion is probably contrary to human nature. Subgroup analysis is a machine for generating false negatives
![Page 5: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/5.jpg)
“. . . some investigators selectively report
only the more interesting subgroup
analyses, thereby leaving the reader (and
us) unaware of how many less exciting
subgroup analyses were looked at and not
mentioned”. Disappointingly, most trials
reporting subgroup analyses noted a
subgroup difference that was highlighted in
the conclusions—so much for cautious
interpretation! Lancet 2000;355:1064
![Page 6: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/6.jpg)
Subgroup analysis
Do we need them?
Usually small groups or excluded as Elderly, Women , PVD, Stroke CABG, CKD, Bleeding
![Page 7: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/7.jpg)
When to believe a subgroup analysis
![Page 8: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/8.jpg)
Large RCT How many subgroup analyses were performed?
◦ The larger the number, the larger the possibility of a spurious finding.
Is the Magnitude of the Subgroup Difference
Large? The larger the difference between the observed effects in particular subgroups,
the more plausible that the difference is real.
Is the Subgroup Difference Consistent Across
Studies? ◦ Consult meta-analyses and systematic reviews
Is it a post hoc or an ad hoc analysis?
◦ The credibility of any apparent subgroup difference that arises out
of post hoc rather than a priori hypotheses is questionable.
◦ Hypothesis-generating vs. hypothesis testing
![Page 9: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/9.jpg)
Subgroup analysis after a borderline or negative RCTrial
![Page 10: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/10.jpg)
CAPRIE: primary efficacy end-point.
Subgroup-analysis
-60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 Aspirin better Clopidogrel better
Relative Risk Reduction (%)
Stroke (p/ys=12033)
AMI (p/ys 11630)
PAD (p/ys 11592)
All patients (p/ys=35155)
p=0,26
p=0,66
p=0,0028
p=0,043
CAPRIE Lancet 1996;348:1329–1339.
![Page 11: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/11.jpg)
Population RR (95% CI) p value
Documented AT 0.88 (0.77, 0.998)
0.046
(n=12153)
Risk Factors Only 1.20 (0.91, 1.59) 0.20 (n=3284)
Overall Population* 0.93 (0.83, 1.05) 0.22 (n=15603)
Primary Efficacy Results (MI/Stroke/CV Death) by Pre-Specified Entry Category
* A statistical test for interaction showed marginally significant heterogeneity (p=0.045) in treatment response for the pre-specified subgroups of symptomatic and asymptomatic patients AT=Atherothrombosis
0.6 0.8 1.4 1.2 Clopidogrel + ASA Better
Placebo + ASA Better
1.6 0.4
Adapted from Bhatt DL, Fox KA, Hacke W, et al. NEJM 2006 – In press
![Page 12: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/12.jpg)
![Page 13: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/13.jpg)
![Page 14: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/14.jpg)
![Page 15: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/15.jpg)
Most subgroup findings tend to exaggerate reality. Be especially suspicious of investigators highlighting a subgroup treatment effect in a trial with no overall treatment effect. They are usually superfluous subgroup salvages of otherwise indeterminate (negative) trials
![Page 16: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/16.jpg)
Subgroup analysis after a positive trial
![Page 17: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/17.jpg)
![Page 18: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/18.jpg)
![Page 19: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/19.jpg)
![Page 20: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/20.jpg)
![Page 21: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/21.jpg)
DM
n:3146
n:4662
n: 7647
Diabetes Mellitus
![Page 22: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/22.jpg)
Ticagrelor (solid lines) and
clopidogrel (dotted lines) groups in
patients with levels of HbA1c at
baseline above median of 6% (blue
lines) and below median of 6% (red
lines).
JJames S et al. Eur Heart J 2010;eurheartj.ehq325
major bleeding
CV death, MI, and stroke
![Page 23: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/23.jpg)
Not all trials provide perfect consistency
Robert Doisneau, Paris 1948
![Page 24: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/24.jpg)
Subgroup analyses are an important part of the analysis of a RCT. However, they are commonly overinterpreted and can lead to further research that is misguided or, worse, to suboptimal patient care. Consider a RCT designed to determine whether a new treatment is more effective than an established treatment and assessed with a test, based on all randomized patients, of the null hypothesis that the treatments have equal efficacy, as measured in terms of the primary end point. Then, subgroup analyses are conducted to assess whether different types of patients respond differently to the new treatment. This sounds simple enough, but there are several important sources of confusion and uncertainty regarding such subgroup analyses
![Page 25: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/25.jpg)
Ευρήματα από ανάλυση υπο-ομάδων
• Βασική αρχή: Εάν υπάρχει μια (μέτρια) διαφορά
ανάμεσα σε δύο θεραπείες όσον αφορά κάποιο σύμβαμα,
τότε η διαφορά αυτή μπορεί να είναι μεγαλύτερη ή
μικρότερη σε διακριτές υπo-ομάδες ασθενών αλλά είναι
απίθανο να είναι αντίθετη
![Page 26: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/26.jpg)
Προτεινόμενες συστάσεις
σχετικά με την ανάλυση υπο-ομάδων
• Περιορισμός αναλύσεων σε ΠΡΟ-καθορισμένες υπο-
ομάδες με γνώμονα κάποια λογική παθοφυσιολογική βάση
προηγούμενης έρευνας
• Ανάλυση μόνο εφόσον υπάρχει στατιστική σημαντικότητα
στο συνολικό αποτέλεσμα
• Διόρθωση τιμής p για πολλαπλές συγκρίσεις (0.05/n, πχ
εάν γίνουν 20 συγκρίσεις να απαιτείται p<0.05/20=0.0025)
• Να θεωρείται ότι τα ευρήματα απαιτούν περαιτέρω έρευνα
και ότι δεν είναι αποδεικτικά
• Να μην δίνεται υπερβολική σημασία
![Page 27: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/27.jpg)
Medical research and patients are best served when subgroup analyses are well planed and appropriately analyzed and when conclusion and recommendations about clinical practice are guided by the strength of the evidence.
![Page 28: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/28.jpg)
TRITON: Numerical reduction in CV death and significant
reduction in MI [5% (40% relative)] with prasugrel in DM pts
Relatively lower reduction in MI with ticagrelor in PLATO may
be explained by
◦ Higher average loading dose of clopidogrel in the clopidogrel arm
◦ Pre-treatment with clopidogrel in 50% pts in the ticagrelor arm
◦ TRITON results depend on early periprocedural MI, detection facilitated by
delay of subject enrolment until after CANG. PLATO enrolled pts soon after
the index event, making early MI detection more difficult. Thus, any
apparent difference in MI results between trials likely results from study
design rather than actual outcome.
PLATO diabetes…
![Page 29: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/29.jpg)
High platelet reactivity in DM
◦ Higher dose of ticagrelor could have resulted in greater clinical benefit???
Predicted steady-state plasma exposure of ticagrelor and its active metabolite not
different in patients with or without DM (AZ internal data)
Very high levels of platelet inhibition may not be sufficient
for adequate protection against ischaemic events in
patients with DM.
◦ The prothrombotic condition that DM constitutes may require anti-thrombin or
other long-term anti-coagulation therapy for a more general prevention of CV
events...
PLATO diabetes…
![Page 30: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/30.jpg)
![Page 31: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/31.jpg)
![Page 32: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/32.jpg)
ROCKET- AF trial- Rivaroxaban in AF Pts with Moderate Renal Impairment
• 14264 ασθενείς με ΚΜ με CHADS2 score ≥ 2 και μέτρια νεφρική δυσλειτουργία: rivaroxaban 20 mg/day or 15 mg/day if CrCl 30–49 mL/min or dose-adjusted warfarin (INR: 2.0– 3.0)
- Μεγαλύτερη συχνότητα μειζόνων και κλινικά σημαντικών αιμορραγιών σε ασθενείς με ΝΑ, ανεξάρτητα από το είδος της θεραπείας
- Παρόμοια συχνότητα αιμορραγιών με μειωμένη δοσολογία rivaroxaban και θεραπείας με warfarin
- Λιγότερες θανατηφόρες αιμορραγίες με rivaroxaban (0.28 vs. 0.74% per 100 p-y; P = 0.047)
Fox K, et al: Eur Heart J 2011; 32: 2387– 2394
![Page 33: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/33.jpg)
Yusuf S, et al. NEJM 2001; 345: 494‐502
Overall
Diabetes
No Diabetes
12562 11.4 9.3
2840 9722 9.9 7.9
14.2 16.7
![Page 34: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/34.jpg)
Aspirin effect on stroke in women
The Canadian Cooperative Study Group. NEJM 1978;299:53-59.
Antiplatelet Trialists’ Collaboration. BMJ. 1994;308:81-106.
![Page 35: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/35.jpg)
Is There External Evidence That Supports the Hypothesized Subgroup Difference? ◦ Does the subgroup effect make sense?
Different populations (including animal studies)
Similar interventions (drug-class effect)
Similar outcomes (surrogate outcomes)
![Page 36: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/36.jpg)
![Page 37: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/37.jpg)
15.9%
22.3%
0%
5%
10%
15%
20%
25%
Ann
ual e
vent
rat
e %
Clopidogrel’s benefit over ASA is amplified in patients with a previous CABG
Bhatt et al. J Am Coll Cardiol 2000;35(Suppl A):383 Bhatt, unpublished data
Overall benefit: p = 0.001; multivariate analysis
Stroke, MI, VD, hospitalization for ischemic events/bleeding Events prevented / 1000 patients per year over ASA
Clopidogrel
ASA
6
![Page 38: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/38.jpg)
![Page 39: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/39.jpg)
![Page 40: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/40.jpg)
Symptomatic Cohort: Primary Outcome (MI/Stroke/CV Death)† by Entry Criteria*
†MI (fatal or non-fatal), stroke (fatal or non-fatal), or cardiovascular death *Patients may have met more than one inclusion criteria All patients received ASA 75-162 mg/day
Cerebrovascular (n=4320)
Placebo +ASA (9.6%)
RRR: 16.0% p=0.088
Clopidogrel + ASA (8.1%)
0
2
4
6
8
10
12
Months since randomization 0 6 12 18 24 30
Coronary (n=5835)
Clopidogrel + ASA (6.5%)
Placebo + ASA (7.4%)
Prim
ary o
utc
om
e e
ven
t rate
(%
)
Months since randomization
RRR: 13.9% p=0.130
0
2
4
6
8
10
12
0 6 12 18 24 30
PAD (n=2838)
Placebo + ASA (8.7%)
Clopidogrel + ASA (7.6%)
RRR: 13.1% p=0.285
0
2
4
6
8
10
12
Months since randomization
0 6 12 18 24 30
Bhatt DL. Presented ateeting - March 2006
![Page 41: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/41.jpg)
![Page 42: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/42.jpg)
![Page 43: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/43.jpg)
![Page 44: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/44.jpg)
![Page 45: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/45.jpg)
![Page 46: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/46.jpg)
![Page 47: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/47.jpg)
CABG and P2Y12 Inhibitors seccation
![Page 48: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/48.jpg)
![Page 49: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/49.jpg)
Common group for subanalysis
Elderly - Women Diabetes mellitus Stroke (history or not)
PVD CABG CKD (patients with CKD were excluded from75%
of published CAD trials) Kidney Intern 2006
![Page 50: Randomized Clinical Trials: the Holy Grailstatic.livemedia.gr/livemedia2/cfiles2/livemedia_ac1us6_20120129094135... · Randomized Clinical Trials: the Holy Grail PRIMARY EFFICACY](https://reader034.vdocuments.site/reader034/viewer/2022051913/6004539ce86aa10e5238fbd6/html5/thumbnails/50.jpg)